Adam Mead

Professor Adam Mead is a Consultant Physician and CRUK Senior Cancer Research Fellow at the University of Oxford, affiliated with the Radcliffe Department of Medicine and the MRC Molecular Haematology Unit. His research focuses on understanding the genetic and cellular mechanisms of myeloproliferative neoplasms (MPN) and related myeloid cancers.

• Academic Rank: Professor of Haematology
• Key Research Areas: Cancer Stem Cell Heterogeneity, Inflammation-Driven Disease Evolution, Single-Cell Genomics, Clinical Translation

Using single-cell technologies, his group has identified inflammation-induced therapy resistance and genetic evolution in MPN. He leads clinical trials including ROBUST, MAJIC, and PROMise, advancing JAK2 inhibitor therapies. In 2024, he was elected a Fellow of the Academy of Medical Sciences.

• Scientific Awards:
  • Fellow of the Academy of Medical Sciences (2024)
  • CRUK Senior Cancer Research Fellow
• Clinical Leadership: Principal Investigator for over 50 trials in MPN and myeloid cancers